Blood Test Detects Precancer Signal for Ovarian Cancer

A molecular RNA marker called Tu-Stroma flags precancerous changes in the fallopian tubes before ovarian cancer develops.

Updated on Nov. 11, 2026 in Cancer

Close view of a single unlabeled glass vial of dark red blood sample on a stainless-steel laboratory bench, with a centrifuge softly blurred behind it. — Researchers reported in Nature Medicine that a blood-based RNA marker called Tu-Stroma can flag precancerous changes in the fallopian tubes linked to ovarian cancer. AI Illustration. Upload story photo >

Live Poll

Would you get a blood test to screen for early ovarian cancer risk?

Researchers have identified an RNA molecule in the blood, called Tu-Stroma, that signals precancerous changes known as serous tubal intraepithelial carcinoma, which often precede ovarian cancer. The findings were published in Nature Medicine.

Why it matters

Ovarian cancer is frequently found only after tumors have grown, and efforts to catch it earlier have largely focused on smaller tumors. A blood-based marker that targets the precancerous stage could shift detection to an earlier point in the disease.

The study reports that Tu-Stroma detected precancerous lesions in 92.3% of affected women and correctly identified 98.2% of healthy women, with roughly 72% of positive results accurate among women with genetic risk factors. Whether these accuracy rates hold in broader populations and whether earlier detection changes survival remains unresolved.

The players

Nature Medicine

A peer-reviewed medical journal that publishes research across clinical and translational medicine.

The details

Ovarian cancer often begins with microscopic changes in the lining of the fallopian tubes, known as serous tubal intraepithelial carcinoma (STIC). Women with STIC have elevated blood levels of the Tu-Stroma RNA molecule, which researchers measured in blood samples to detect the lesions. The findings were published in Nature Medicine.

- Study published in Nature Medicine on November 10, 2026.

Health Landscape

Ovarian cancer detection has long relied on finding smaller tumors, and this research moves the target earlier to STIC lesions in the fallopian tubes. The approach reflects a broader push in cancer research to identify biological signals before malignancy is established.

For women with genetic risk factors for ovarian cancer, a future blood test could offer information earlier than current approaches. Any clinical use would depend on further validation before it changes screening or surgical decisions.

The takeaway

Earlier detection research aims to find cancer at its precancerous stage, when intervention may be more effective. Readers with a family history of ovarian cancer may wish to discuss their risk factors with a clinician.